Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.39−0.04 (-8.71%)
Close on Nov 20, 2026Market cap $106.82MP/E –Yield –
Akebia Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Akebia Therapeutics's gross profit for the twelve months ending Jun 30, 2026 was $174.43M, up 15.0% year over year. For fiscal 2025 it was $196.73M, up 102.8% from the year before. The highest annual figure on record is $206.92M in fiscal 2022.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.73M | +102.8% |
| FY2024 | Dec 31, 2024 | $97.00M | -19.5% |
| FY2023 | Dec 31, 2023 | $120.47M | -41.8% |
| FY2022 | Dec 31, 2022 | $206.92M | +239.3% |
| FY2021 | Dec 31, 2021 | $60.98M | – |
| FY2020 | Dec 31, 2020 | -$1.83M | -101.0% |
| FY2019 | Dec 31, 2019 | $189.67M | -5.2% |
| FY2018 | Dec 31, 2018 | $199.97M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $38.70M | -26.4% |
| Q1 FY2026 | Mar 31, 2026 | $41.25M | -17.0% |
| Q4 FY2025 | Dec 31, 2025 | $45.09M | +72.5% |
| Q3 FY2025 | Sep 30, 2025 | $49.38M | +112.2% |
| Q2 FY2025 | Jun 30, 2025 | $52.55M | +97.6% |
| Q1 FY2025 | Mar 31, 2025 | $49.71M | +136.7% |
| Q4 FY2024 | Dec 31, 2024 | $26.13M | -30.4% |
| Q3 FY2024 | Sep 30, 2024 | $23.27M | -3.2% |
| Q2 FY2024 | Jun 30, 2024 | $26.60M | -32.0% |
| Q1 FY2024 | Mar 31, 2024 | $21.00M | +6.0% |
| Q4 FY2023 | Dec 31, 2023 | $37.53M | +16.6% |
| Q3 FY2023 | Sep 30, 2023 | $24.04M | +130.4% |
| Q2 FY2023 | Jun 30, 2023 | $39.09M | -63.7% |
| Q1 FY2023 | Mar 31, 2023 | $19.82M | -48.7% |
| Q4 FY2022 | Dec 31, 2022 | $32.18M | +220.2% |
| Q3 FY2022 | Sep 30, 2022 | $10.43M | -68.2% |
| Q2 FY2022 | Jun 30, 2022 | $107.77M | +25681.1% |
| Q1 FY2022 | Mar 31, 2022 | $38.59M | +118.1% |
| Q4 FY2021 | Dec 31, 2021 | $10.05M | – |
| Q3 FY2021 | Sep 30, 2021 | $32.81M | +10.7% |
| Q2 FY2021 | Jun 30, 2021 | $418.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $17.70M | -70.9% |
| Q4 FY2020 | Dec 31, 2020 | -$7.20M | -122.9% |
| Q3 FY2020 | Sep 30, 2020 | $29.64M | -44.8% |
| Q2 FY2020 | Jun 30, 2020 | -$84.47M | -233.8% |
| Q1 FY2020 | Mar 31, 2020 | $60.77M | +46.7% |
| Q4 FY2019 | Dec 31, 2019 | $31.41M | -39.7% |
| Q3 FY2019 | Sep 30, 2019 | $53.71M | – |
| Q2 FY2019 | Jun 30, 2019 | $63.13M | – |
| Q1 FY2019 | Mar 31, 2019 | $41.41M | – |
| Q4 FY2018 | Dec 31, 2018 | $52.08M | – |
See a number that looks wrong?